The inflammatory bowel disease patient-centered medical home is a new and novel collaborative approach to the problem of fragmented, ineffective and costly care. It pairs patients with a multispecialty team of healthcare providers who emphasize preventive care and nutrition and treat co-existing pain and psychological issues.
Clinicians increasingly are recognizing the need to recognize and manage inflammatory bowel disease’s extra-intestinal manifestations. A new Cleveland Clinic review provides guidance.
Cleveland Clinic experts developed an endoscopic treatment that’s a better approach for opening fistula in IBD patients. It can go deeper into the bowel, beyond the reach of the non-laparostomy surgical approach. Dr. Bo Shen explains.
A nomogram presented at ASCRS 2018 can help physicians easily calculate the risk of postsurgical VTE for their patients with IBD.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Dr. Bo Shen explains what’s new in treating IBD ― and invites you to learn more at the Dr. Victor Fazio IBD Symposium in Medical & Surgical Treatment of Crohn’s Disease and Ulcerative Colitis during DDW 2018.
Dr. Tracy Hull explains why you should join us at the Dr. Victor Fazio IBD Symposium to hear what’s new in the medical and surgical treatment of Crohn’s disease and ulcerative colitis.
When experience and innovation matter: A 65-year-old man with an acute presacral anastomotic leak and large hematoma ultimately has a stoma closure and avoids a permanent ostomy.
Preventable IBD readmissions are problematic for hospitals nationwide. Gastroenterologist Maged Rizk, MD, has identified which factors increase risk of readmission so the right patients can be more closely monitored.
Biologic Therapies VII Summit in April 2-17 will help clinicians understand and harness the hopes and challenges of precision medicine for the nearly 50 million people in the U.S. with disorders of immunity.
Biosimilar agents, which are awaiting approval in the United States, provide a lower-cost option to treat inflammatory bowel disease, increasing access to therapies potentially as effective as biologic agents.